Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Omega 3 Prescription Drugs Market

ID: MRFR/Pharma/17410-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

US Omega-3 Prescription Drugs Market Research Report By Drug (Vascepa, Lovaza, Others), By Application Type (Hypertriglyceridemia, Others) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Omega 3 Prescription Drugs Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Industrial Automation & Equipment, BY Drug (USD Million)
  49.     4.1.1 Vascepa
  50.     4.1.2 Lovaza
  51.     4.1.3 Others
  52.   4.2 Industrial Automation & Equipment, BY Application Type (USD Million)
  53.     4.2.1 Hypertriglyceridemia
  54.     4.2.2 Others
  55.   4.3 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
  56.     4.3.1 Hospital Pharmacy
  57.     4.3.2 Retail Pharmacy
  58.     4.3.3 Online Pharmacy
  59. 5 SECTION V: COMPETITIVE ANALYSIS
  60.   5.1 Competitive Landscape
  61.     5.1.1 Overview
  62.     5.1.2 Competitive Analysis
  63.     5.1.3 Market share Analysis
  64.     5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  65.     5.1.5 Competitive Benchmarking
  66.     5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  67.     5.1.7 Key developments and growth strategies
  68.       5.1.7.1 New Product Launch/Service Deployment
  69.       5.1.7.2 Merger & Acquisitions
  70.       5.1.7.3 Joint Ventures
  71.     5.1.8 Major Players Financial Matrix
  72.       5.1.8.1 Sales and Operating Income
  73.       5.1.8.2 Major Players R&D Expenditure. 2023
  74.   5.2 Company Profiles
  75.     5.2.1 Amgen Inc (US)
  76.       5.2.1.1 Financial Overview
  77.       5.2.1.2 Products Offered
  78.       5.2.1.3 Key Developments
  79.       5.2.1.4 SWOT Analysis
  80.       5.2.1.5 Key Strategies
  81.     5.2.2 Bristol-Myers Squibb Company (US)
  82.       5.2.2.1 Financial Overview
  83.       5.2.2.2 Products Offered
  84.       5.2.2.3 Key Developments
  85.       5.2.2.4 SWOT Analysis
  86.       5.2.2.5 Key Strategies
  87.     5.2.3 GlaxoSmithKline plc (GB)
  88.       5.2.3.1 Financial Overview
  89.       5.2.3.2 Products Offered
  90.       5.2.3.3 Key Developments
  91.       5.2.3.4 SWOT Analysis
  92.       5.2.3.5 Key Strategies
  93.     5.2.4 Pfizer Inc (US)
  94.       5.2.4.1 Financial Overview
  95.       5.2.4.2 Products Offered
  96.       5.2.4.3 Key Developments
  97.       5.2.4.4 SWOT Analysis
  98.       5.2.4.5 Key Strategies
  99.     5.2.5 Bayer AG (DE)
  100.       5.2.5.1 Financial Overview
  101.       5.2.5.2 Products Offered
  102.       5.2.5.3 Key Developments
  103.       5.2.5.4 SWOT Analysis
  104.       5.2.5.5 Key Strategies
  105.     5.2.6 Novartis AG (CH)
  106.       5.2.6.1 Financial Overview
  107.       5.2.6.2 Products Offered
  108.       5.2.6.3 Key Developments
  109.       5.2.6.4 SWOT Analysis
  110.       5.2.6.5 Key Strategies
  111.     5.2.7 Sanofi S.A. (FR)
  112.       5.2.7.1 Financial Overview
  113.       5.2.7.2 Products Offered
  114.       5.2.7.3 Key Developments
  115.       5.2.7.4 SWOT Analysis
  116.       5.2.7.5 Key Strategies
  117.     5.2.8 AstraZeneca plc (GB)
  118.       5.2.8.1 Financial Overview
  119.       5.2.8.2 Products Offered
  120.       5.2.8.3 Key Developments
  121.       5.2.8.4 SWOT Analysis
  122.       5.2.8.5 Key Strategies
  123.     5.2.9 Mylan N.V. (US)
  124.       5.2.9.1 Financial Overview
  125.       5.2.9.2 Products Offered
  126.       5.2.9.3 Key Developments
  127.       5.2.9.4 SWOT Analysis
  128.       5.2.9.5 Key Strategies
  129.   5.3 Appendix
  130.     5.3.1 References
  131.     5.3.2 Related Reports
  132. 6 LIST OF FIGURES
  133.   6.1 MARKET SYNOPSIS
  134.   6.2 US MARKET ANALYSIS BY DRUG
  135.   6.3 US MARKET ANALYSIS BY APPLICATION TYPE
  136.   6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  137.   6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
  138.   6.6 RESEARCH PROCESS OF MRFR
  139.   6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
  140.   6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  141.   6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  142.   6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
  143.   6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG, 2024 (% SHARE)
  144.   6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG, 2024 TO 2035 (USD Million)
  145.   6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION TYPE, 2024 (% SHARE)
  146.   6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION TYPE, 2024 TO 2035 (USD Million)
  147.   6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  148.   6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  149.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  150. 7 LIST OF TABLES
  151.   7.1 LIST OF ASSUMPTIONS
  152.     7.1.1
  153.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  154.     7.2.1 BY DRUG, 2025-2035 (USD Million)
  155.     7.2.2 BY APPLICATION TYPE, 2025-2035 (USD Million)
  156.     7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  157.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  158.     7.3.1
  159.   7.4 ACQUISITION/PARTNERSHIP
  160.     7.4.1

US Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Drug (USD Million, 2025-2035)

  • Vascepa
  • Lovaza
  • Others

Industrial Automation & Equipment By Application Type (USD Million, 2025-2035)

  • Hypertriglyceridemia
  • Others

Industrial Automation & Equipment By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions